Key result
Azelnidipine provides 24-hour BP control and cardioprotection without inducing reflex tachycardia.
Why the study?
To summarize the pharmacological characteristics, pharmacokinetics, pharmacodynamics, mechanism of action, clinical efficacy, safety profile, and therapeutic role of azelnidipine in treating hypertension.
Azelnidipine is a third-generation dihydropyridine calcium channel blocker with dual L- and T-type channel blockade that offers sustained blood pressure control with cardioprotective and renoprotective benefits without reflex tachycardia.
Supports azelnidipine for sustained BP control without tachycardia; leaves open confirmation of cardioprotective effects in RCTs.
Azelnidipine is a third-generation dihydropyridine calcium channel blocker (CCB) characterized by high vascular selectivity, long duration of action, and unique dual L-type and T-type calcium channel blockade. It provides effective and sustained antihypertensive action without inducing reflex tachycardia, a common limitation of earlier CCBs. Owing to its high lipophilicity and prolonged membrane binding, Azelnidipine maintains 24-hour blood pressure control and demonstrates cardioprotective, renoprotective, and anti-oxidative properties. The drug has also shown favorable effects on left ventricular hypertrophy, endothelial function, and renal microcirculation. This review summarizes the pharmacological characteristics, pharmacokinetics, and pharmacodynamics, mechanism of action, clinical efficacy, safety profile, and therapeutic role of Azelnidipine in the treatment of hypertension.
No takes yet. Share an insight, caveat, or question.
Krupa Akbari1, Twinsi Prajapati2, Shreya Patel3, Shruti Patel4, Kuldeep Choubisa5* (2026) studied this question. Azelnidipine provides effective 24-hour blood pressure control and demonstrates cardioprotective properties without inducing reflex tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: